Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial

NCT06399679 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06399679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Suspended
Start date
November 4, 2024
Completion date
December 31, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticholinergic toxicity